Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
BCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
TOR controls translation initiation and early G1 progression in yeast.
Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., & Hall, M. N. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.25 · Cited by 715
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Paulovich, A. G., Toczyski, D. P., & Hartwell, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)81870-x · Cited by 616
Cited by
The role of autophagy in cancer development and response to therapy
Kondo, Y., Kanzawa, T., Sawaya, R., & Kondo, S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1692 · Cited by 1,654
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway
Wolfson, R. L., & Sabatini, D. M. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.001 · Cited by 547
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Drug/device combinations for local drug therapies and infection prophylaxis
Wu, P., & Grainger, D. W. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2005.11.031 · Cited by 491
“Its mechanism of action is via receptor-based antagonism of the intracellular enzyme, mammalian target of rapamycin (mTOR [27]), the downstream mediator of the cell’s PI3K/ Akt phosphorylation signaling pathway that regulates many basic cell functions.”
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
Cao, C., Subhawong, T., Albert, J. M., Kim, K. W., Geng, L., Sekhar, K. R., Gi, Y. J., & Lu, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0802 · Cited by 332
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 317
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 300
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck
Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. A., Molinolo, A. A., & Gutkind, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0921 · Cited by 238
“The recent clinical evaluation in phase I trials of rapamycin derivatives, including CCI779 and RAD001, revealed that these novel anticancer agents display encouraging antitumor activity with minimal toxicity and no immunosuppression over a broad range of dose levels (46, 58, 59).”
Metabolic catastrophe as a means to cancer cell death
Jin, S., DiPaola, R. S., Mathew, R., & White, E. (2007) · Journal of Cell Science · doi:10.1242/jcs.03349 · Cited by 229
“Agents such as rapamycin and analogues including CCI-779 and RAD001, for example, inhibit downstream signaling and are currently in clinical trials (Chan, 2004; Rowinsky, 2004).”
Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
Murphy, J. D., Spalding, A. C., Somnay, Y. R., Markwart, S., Ray, M. E., & Hamstra, D. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1019 · Cited by 44
(2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.04.03 · Cited by 24
Metadata
- Authors
- Chan, S.
- Venue
- British Journal of Cancer
- Published
- 2004-09-14
- Volume
- 91
- Issue
- 8
- Pages
- 1420-1424
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2013453542
- Cited by
- 301
- References
- 23
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.